Trial Profile

A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Berzosertib (Primary) ; Cisplatin (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions

Most Recent Events

27 Jun 2025 Planned End Date changed from 23 Apr 2025 to 14 May 2026.
07 May 2024 Planned End Date changed from 12 Mar 2025 to 23 Apr 2025.
13 Mar 2024 Planned End Date changed from 31 Dec 2023 to 12 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com